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Summary and Implication 
 Egg lecithin differs from soy lecithin in its 
phospholipid profile and fatty acid composition.  The 
current study was designed to test whether egg lecithin or 
soy lecithin decreased the plasma cholesterol concentration 
in hamsters that are used as a model for humans. Male 
golden Syrian hamsters were assigned randomly to eight 
dietary treatments lasting 4 weeks (n=10 per treatment) that 
contained 0.12% (wt/wt) of cholesterol and varied amount 
of supplemental lipids. The diet groups were: control with 
no supplemental lipid, 0.05%, 0.5%, and 5% (wt/wt) of egg 
lecithin or soy lecithin, respectively, and 5% (wt/wt) of 
soybean oil. Dietary soy lecithin decreased the plasma 
cholesterol concentration compared with control in a 
dosage- and time-dependent manner. The 5% soy lecithin 
treatment greatly decreased the final plasma total 
cholesterol and LDL-cholesterol compared with the control 
(p<0.0001). In addition, the 5% soy lecithin 
supplementation caused greater decrease in plasma total 
cholesterol than did the 5% soybean oil treatment (p<0.05), 
indicating effects beyond the fatty acid composition. The 
cholesterol absorption measured on day 24, however, was 
lower in the control group compared with all other 
treatments (p<0.05). Overall, dietary soy lecithin but not 
egg lecithin decreased the plasma cholesterol concentration 
in hamsters via a mechanism other than decreasing 
cholesterol absorption.  
 
Introduction 
It has been long recognized that blood cholesterol 
concentration is an important risk factor for development of 
atherosclerosis. Several studies have shown that soy 
lecithin, a phospholipid mixture extracted from soybean 
oil, has hypocholesterolemic properties in animals and 
humans. The underlying mechanism for the cholesterol 
lowering effect of soy lecithin, however, has not been 
elucidated.  
Cholesterol homeostasis is determined by the balance 
of intestinal cholesterol absorption, endogenous cholesterol 
synthesis, and excretion of biliary sterols. Cholesterol 
absorption is believed to be correlated positively to plasma 
cholesterol concentration. Recent studies showed that 
phosphatidylcholine (PC) suppressed cholesterol 
absorption in vitro and in vivo, which, in turn, might 
decrease the blood cholesterol concentration.  
Soy lecithin consists of three types of phospholipids 
(PL): PC, phosphatidylethanolamine (PE), and 
phosphotidylinositol (PI), with similar amounts of each PL. 
In contrast, egg lecithin contains PC and PE, with PC as the 
major component. The concentration of total unsaturated 
fatty acids is much higher in soy lecithin than in egg 
lecithin. The objective of this study was to test whether egg 
lecithin or soy lecithin decreased the plasma cholesterol 
concentration in hamsters used as a model for human. 
 
Materials and Methods 
Animals and diets. Male golden Syrian hamsters (10 
weeks old, weighing ~100 g) were housed individually in 
metabolic rodent cages. All animals were maintained in a 
temperature-controlled room (23°C) with a 12-hour/12-
hour light/dark cycle. Hamsters were provided free access 
to food and water through the entire experiment period and 
were allowed 1 week of adaptation to the environment 
prior to the treatment.  Hamsters were assigned randomly 
to eight dietary treatments lasting 4 weeks (n=10 per 
treatment) that contained 0.12% (wt/wt) of cholesterol and 
varied amount of supplemental lipids. The diet groups 
were: control with no supplemented lipid, 0.05%, 0.5%, 
and 5% (wt/wt) of egg lecithin or soy lecithin, respectively, 
and 5% (wt/wt) of soybean oil. The rodent chow was 
ground to powder by a mechanical blender. Cholesterol and 
supplemented lipids were added to the ground chow in 
warm ethanol and hexane, respectively, which were 
evaporated before feeding the hamsters.  
Plasma lipid and lipoprotein analysis. Blood samples 
were collected on day 0, 14, and 28 of the study period. 
Plasma total cholesterol, HDL-cholesterol, and TAG 
concentrations were determined enzymatically. Non-HDL-
cholesterol (VLDL + LDL) was calculated by difference.   
Cholesterol absorption. Cholesterol absorption 
efficiency was measured on day 2 and 24 of the study. 
Hamsters were given intragatrically by gavage 150 µl of 
medium-chain triacyglecerol (MCT) oil containing a 
mixture of 1 µCi of [14C] cholesterol and 2 µCi [3H] 
sitostanol. Feces were collected for the following 4 days, 
dried for three days, and then finely ground. Lipids were 
extracted from the ground feces and the original dosing 
mixtures and dissolved in chloroform. Duplicate aliquots of 
each sample were transferred to counting vials and dried. 
After samples were redissolved in methanol, H2O2 was 
added for decolorization. The vials then were incubated at 
37 ºC until the color of pigments in the samples 
disappeared. Methanol and H2O2 were evaporated, and 
scintillation cocktail was added to the vials for counting of 
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radioactivity. The cholesterol absorption efficiency was 
calculated as: % cholesterol absorption = {(14C/ 3H dosing 
mixture - 14C/ 3H feces)/ 
( 14C/ 3H dosing mixture)}× 100 
Statistics analysis. PROC MIXED in SAS was used to 
analyze the data, which included treatments as fixed effects 
and blocks as random effects. If the F value of ANOVA 
was significant, group differences were analyzed further by 
a multiple comparison test. Differences were considered 
significant at p<0.05.  
 
Results and Discussion 
The total plasma cholesterol concentrations in hamsters 
were affected by dietary treatments in a time- and dosage-
dependent manner (Table 1). Feeding 5% egg lecithin for 
two weeks resulted in a higher plasma cholesterol 
concentration compared with that of the other treatments 
(p<0.05), but the final cholesterol concentration in the 5% 
egg lecithin group did not significantly differ from that of 
the control. Supplementing 5% soy lecithin or 5% soybean 
oil for four weeks decreased the plasma cholesterol 
concentration in hamsters compared with control 
(p<0.0001 and p<0.05, respectively). In addition, the final 
cholesterol concentration in the 5% soy lecithin treatment 
group was lower than that in the 5% soybean oil group 
(p<0.05). The 0.5% and 0.05% dosages of both soy lecithin 
and egg lecithin supplementations did not result in any 
significant differences compared with control.  
 
Table 1. Treatment effects on hamster plasma 
cholesterol concentration at different time points1. 
Plasma Cholesterol 
Concentration (mg/dl) 
Treatment 
Day 0 Day 14 Day 28 
Control 86.07 148.07b,c 226.71a
0.05% egg lecithin 81.31 151.91b,c 235.44a
0.5%egg lecithin 87.07 156.4b 223.37a,b
5% egg lecithin 82.34 166.29a 234.09a
0.05% soy lecithin 83.09 151.25b,c 219.76a,b
0.5% soy lecithin 83.88 140.80c 218.11a,b
5% soy lecithin 84.74 139.81c 189.77c
5% soybean oil 80.06 148.9b,c 208.53b
S.E.M. 4.81 4.73 11.29 
1Values in the same column not sharing a common 
superscript differed at p<0.05; n=10 for each treatment; 
S.E.M., standard error of the mean. 
 
There were no significant differences in the final 
concentrations of plasma HDL-cholesterol and 
triacylglycerol (TAG) between the different treatment 
groups (Table 2). In contrast, dietary 5% soy lecithin 
decreased (p<0.05) the non-HDL (VLDL and LDL)-
cholesterol concentration compared with those of the other 
treatment groups except the 5% soybean oil treatment 
(p>0.05). These data suggest that 5% soy lecithin 
decreased the total cholesterol by decreasing the non-HDL-
cholesterol.  
Lipid supplements did not result in significant 
differences in cholesterol absorption in the short term 
(Table 3). In contrast, cholesterol absorption measured by 
the end of the study (day 24) was lower in the control 
group compared with that of the other groups (p<0.05), 
which indicated that dietary soy lecithin decreased the 
plasma total and non-HDL-cholesterol concentration via a 
mechanism other than decreasing cholesterol absorption.  
 
Table 2. Treatment effects on hamster plasma HDL-
cholesterol (chol), non-HDL-cholesterol, and TAG 
concentration on day 281.  
Treatment 
HDL-
Chol 
(mg/dl) 
Non-HDL-  
Chol 
(mg/dl) 
TAG 
(mg/dl) 
Control 56.10 170.59a,b 179.59 
0.05% egg lecithin 51.92 183.47a 192.73 
0.5% egg lecithin 57.15 166.19a,b 160.89 
5% egg lecithin 52.05 182.01a,b 196.50 
0.05% soy lecithin 54.50 164.72b 204.37 
0.5% soy lecithin 53.96 164.97b 160.72 
5% soy lecithin 50.08 139.66c 189.00 
5% soy bean oil 55.76 152.75b,c 178.68 
S.E.M. 5.28 10.79 13.67 
1Values in the same column not sharing a common 
superscript differed at p<0.05; n=10 for each treatment; 
S.E.M., standard error of the mean. 
 
Table 3. Treatment effects on cholesterol absorption at 
different time points1.  
Cholesterol absorption 
efficiency (%) Treatment 
Day 2 Day 24 
Control 55.22 44.81c
0.05% egg lecithin 59.22 62.46a,b
0.5% egg lecithin 57.96 66.93a,b
5% egg lecithin 67.84 72.65a
0.05% soy lecithin 56.29 60.67b
0.5% soy lecithin 54.77 58.65b
5% soy lecithin 52.06 62.99a,b
5% soy bean oil 61.01 61.45a,b
S.E.M. 4.69 4.13 
1Values in the same column not sharing a common 
superscript differed at p<0.05; n=10 for each treatment; 
S.E.M., standard error of the mean. 
 
Numerous studies have shown that dietary unsaturated 
fatty acid (UFA) can decrease blood cholesterol 
concentration, whereas high intake of saturated fatty acids, 
especially C12:0, C14:0, and C16:0, will result in elevated 
blood cholesterol concentration. Soybean oil and soy 
lecithin contain high percentages of UFA, which may 
contribute to their cholesterol lowering properties. The 
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decrease of plasma cholesterol concentration, however, was 
more obvious in the hamsters of the 5% soy lecithin group 
than in those of the 5% soybean oil group, indicating 
effects beyond the content of UFA.  
Phosphatidylcholine (PC) plays an important role in the 
emulsification and solubilization of cholesterol in small 
intestine. Several studies, however, showed that adequate 
supply of PC inhibits, instead of increases, cholesterol 
absorption. This inhibition is relieved by the hydrolysis of 
PC by pancreatic phospholipase A2 (pPLA2). Our data  
suggest that the supplemented lipids increased the 
cholesterol absorption by acting as an emulsifier and 
solubilizer for cholesterol. The possible inhibition of PC on 
cholesterol absorption was abolished by sufficient 
hydrolysis of PC in the small intestine of hamsters.  
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